Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NRIX |
---|---|---|
09:32 ET | 5549 | 15.83 |
09:34 ET | 2283 | 15.91 |
09:36 ET | 1900 | 15.97 |
09:38 ET | 1150 | 15.9 |
09:39 ET | 9334 | 15.98 |
09:41 ET | 3744 | 16.21 |
09:43 ET | 4277 | 16.085 |
09:45 ET | 3250 | 16.17 |
09:48 ET | 10460 | 16.14 |
09:50 ET | 2876 | 16.035 |
09:52 ET | 2286 | 15.965 |
09:54 ET | 1600 | 15.91 |
09:56 ET | 30908 | 15.95 |
09:57 ET | 2050 | 15.95 |
09:59 ET | 1100 | 15.91 |
10:01 ET | 1600 | 15.95 |
10:03 ET | 3568 | 15.95 |
10:06 ET | 1200 | 15.98 |
10:08 ET | 100 | 16.005 |
10:10 ET | 1693 | 16.045 |
10:12 ET | 2998 | 16.035 |
10:14 ET | 200 | 16.105 |
10:15 ET | 6576 | 16.12 |
10:17 ET | 1853 | 16.11 |
10:19 ET | 31125 | 16.2 |
10:21 ET | 2167 | 16.201 |
10:24 ET | 500 | 16.2099 |
10:26 ET | 1800 | 16.17 |
10:28 ET | 200 | 16.17 |
10:30 ET | 500 | 16.18 |
10:32 ET | 2426 | 16.295 |
10:33 ET | 1491 | 16.26 |
10:35 ET | 2744 | 16.1293 |
10:37 ET | 2445 | 16.08 |
10:39 ET | 25027 | 16.0386 |
10:42 ET | 2480 | 16.07 |
10:44 ET | 300 | 16.07 |
10:46 ET | 13300 | 16.13 |
10:48 ET | 2761 | 16.15 |
10:50 ET | 1250 | 16.19 |
10:51 ET | 1651 | 16.175 |
10:53 ET | 1901 | 16.2 |
10:55 ET | 1376 | 16.2 |
10:57 ET | 3644 | 16.23 |
11:00 ET | 10819 | 16.23 |
11:02 ET | 1759 | 16.26 |
11:04 ET | 104444 | 16.305 |
11:06 ET | 5112 | 16.48 |
11:08 ET | 5451 | 16.435 |
11:09 ET | 1000 | 16.39 |
11:11 ET | 38532 | 16.305 |
11:13 ET | 1699 | 16.395 |
11:15 ET | 3405 | 16.39 |
11:18 ET | 1210 | 16.325 |
11:20 ET | 847 | 16.39 |
11:22 ET | 900 | 16.37 |
11:24 ET | 833 | 16.405 |
11:26 ET | 2049 | 16.31 |
11:27 ET | 1119 | 16.315 |
11:29 ET | 5177 | 16.33 |
11:31 ET | 574 | 16.3486 |
11:33 ET | 401 | 16.4 |
11:36 ET | 1050 | 16.4 |
11:38 ET | 2087 | 16.38 |
11:40 ET | 4500 | 16.3596 |
11:42 ET | 300 | 16.38 |
11:44 ET | 1600 | 16.42 |
11:45 ET | 459 | 16.425 |
11:47 ET | 1800 | 16.4099 |
11:49 ET | 1400 | 16.375 |
11:51 ET | 4822 | 16.42 |
11:54 ET | 2210 | 16.3023 |
11:56 ET | 861 | 16.45 |
11:58 ET | 600 | 16.42 |
12:00 ET | 100 | 16.41 |
12:02 ET | 200 | 16.4 |
12:03 ET | 1005 | 16.54 |
12:05 ET | 933 | 16.53 |
12:07 ET | 768 | 16.55 |
12:09 ET | 1000 | 16.53 |
12:12 ET | 5919 | 16.38 |
12:14 ET | 200 | 16.435 |
12:16 ET | 700 | 16.45 |
12:18 ET | 100 | 16.43 |
12:20 ET | 300 | 16.43 |
12:23 ET | 400 | 16.44 |
12:25 ET | 300 | 16.445 |
12:27 ET | 1525 | 16.455 |
12:30 ET | 500 | 16.46 |
12:32 ET | 2192 | 16.52 |
12:36 ET | 900 | 16.5 |
12:38 ET | 300 | 16.46 |
12:39 ET | 500 | 16.445 |
12:41 ET | 1164 | 16.45 |
12:43 ET | 599 | 16.44 |
12:45 ET | 100 | 16.45 |
12:48 ET | 200 | 16.445 |
12:52 ET | 3478 | 16.5 |
12:54 ET | 100 | 16.545 |
12:56 ET | 3359 | 16.52 |
12:57 ET | 1481 | 16.465 |
12:59 ET | 300 | 16.445 |
01:03 ET | 400 | 16.43 |
01:06 ET | 918 | 16.43 |
01:10 ET | 1200 | 16.425 |
01:12 ET | 300 | 16.39 |
01:14 ET | 400 | 16.39 |
01:15 ET | 100 | 16.345 |
01:19 ET | 500 | 16.33 |
01:21 ET | 2300 | 16.3 |
01:24 ET | 1496 | 16.34 |
01:28 ET | 600 | 16.365 |
01:30 ET | 600 | 16.38 |
01:32 ET | 100 | 16.41 |
01:33 ET | 2000 | 16.34 |
01:35 ET | 1933 | 16.3201 |
01:37 ET | 1637 | 16.35 |
01:39 ET | 100 | 16.39 |
01:42 ET | 1050 | 16.35 |
01:44 ET | 100 | 16.39 |
01:46 ET | 954 | 16.35 |
01:48 ET | 1249 | 16.35 |
01:50 ET | 300 | 16.34 |
01:51 ET | 768 | 16.35 |
01:53 ET | 800 | 16.35 |
01:55 ET | 100 | 16.35 |
01:57 ET | 1000 | 16.3615 |
02:00 ET | 2825 | 16.3599 |
02:02 ET | 100 | 16.39 |
02:04 ET | 1862 | 16.32 |
02:06 ET | 300 | 16.285 |
02:08 ET | 200 | 16.28 |
02:09 ET | 910 | 16.28 |
02:11 ET | 900 | 16.235 |
02:13 ET | 100 | 16.235 |
02:15 ET | 200 | 16.235 |
02:18 ET | 937 | 16.16 |
02:20 ET | 300 | 16.1 |
02:22 ET | 500 | 16.1 |
02:24 ET | 620 | 16.09 |
02:26 ET | 200 | 16.115 |
02:27 ET | 300 | 16.11 |
02:29 ET | 821 | 16.105 |
02:31 ET | 1849 | 16.08 |
02:33 ET | 1407 | 16.0507 |
02:36 ET | 1100 | 16.04 |
02:38 ET | 1916 | 16.095 |
02:40 ET | 100 | 16.095 |
02:42 ET | 1011 | 16.115 |
02:44 ET | 1521 | 16.07 |
02:45 ET | 300 | 16.09 |
02:47 ET | 600 | 16.08 |
02:49 ET | 1700 | 16.07 |
02:51 ET | 100 | 16.06 |
02:54 ET | 400 | 16.09 |
02:56 ET | 1993 | 16.105 |
02:58 ET | 3350 | 16.0905 |
03:00 ET | 2754 | 16.045 |
03:02 ET | 1300 | 16.01 |
03:03 ET | 1300 | 15.95 |
03:05 ET | 500 | 15.895 |
03:07 ET | 300 | 15.89 |
03:09 ET | 2067 | 15.97 |
03:12 ET | 1641 | 15.955 |
03:14 ET | 1131 | 15.96 |
03:16 ET | 746 | 15.94 |
03:18 ET | 1694 | 15.99 |
03:20 ET | 4519 | 15.96 |
03:21 ET | 1200 | 15.91 |
03:23 ET | 2663 | 15.88 |
03:25 ET | 1894 | 15.885 |
03:27 ET | 2021 | 15.88 |
03:30 ET | 3126 | 15.84 |
03:32 ET | 3038 | 15.82 |
03:34 ET | 200 | 15.81 |
03:36 ET | 3965 | 15.78 |
03:38 ET | 3572 | 15.75 |
03:39 ET | 1343 | 15.77 |
03:41 ET | 2871 | 15.72 |
03:43 ET | 3836 | 15.75 |
03:45 ET | 3192 | 15.75 |
03:48 ET | 2600 | 15.745 |
03:50 ET | 5186 | 15.77 |
03:52 ET | 5155 | 15.73 |
03:54 ET | 5091 | 15.805 |
03:56 ET | 16424 | 15.885 |
03:57 ET | 10321 | 15.91 |
03:59 ET | 173847 | 15.9 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nurix Therapeutics Inc | 886.6M | -6.0x | --- |
Arcutis Biotherapeutics Inc | 939.2M | -2.4x | --- |
Regenxbio Inc | 774.9M | -2.8x | --- |
SAGE Therapeutics Inc | 721.6M | -1.4x | --- |
CureVac NV | 695.3M | -2.5x | --- |
Zymeworks Inc | 636.3M | -5.1x | --- |
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $886.6M |
---|---|
Revenue (TTM) | $80.9M |
Shares Outstanding | 59.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.15 |
EPS | $-2.65 |
Book Value | $4.12 |
P/E Ratio | -6.0x |
Price/Sales (TTM) | 11.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -194.51% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.